Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Using body-mass index to tell who is overweight or obese is not reliable and can result in misdiagnosis, the Commission on ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on January 13.Stay Ahead of the ...

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Medical experts proposed a radical overhaul of how obesity is diagnosed, moving away from relying on body mass alone and ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

Many of them are on Medicaid and have become yo-yo dieters who, despite their best efforts at changing their eating habits and lifestyles, cannot seem to shed the pounds hurting their health. “They ...

CR shares expert guidance on the best sleep position, pillows, mattresses, and more if you have sleep apnea, GERD, asthma, ...